![]() Adjuvant Nivolumab verus Ipilimumab in resected stage III or IV melanoma. Weber J, Mandela M, Del Vecchio HJ, Gogas HJ, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO). ![]() Integrated genomic characterization of oesophageal carcinoma. Ramucirumab with cisplatin and flouropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL). Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Kojima T et al Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. Cisplatin and 5‑fluorouracil in the primary management of squamous esophageal cancer. Kies MS, Rosen ST, Tsang TK, Shetty R, et al. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. Pathological complete response in patient with esophageal cancer after the trimodality approach: The associaton with baseline variables and survival. Murphy MB, Xiao L, Patel VR, Maru DM, et al. Nivoluma in patients with advanced gastric or gastro-osophageal junction cancer refractory to, or intolerant of, at least two previous chemotheraoy regimes (Attraction-2). Nivoluma versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refratory to prevoius chemotheraoy (Attraction-3). Kato K, Cho BCC, Takahashi M, Okada M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Shapiro J, van Lanschot JJB, Hulshof MCCM. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Shah MA, Kennedy EB, Catenacci DV, Dana C, et al. In contrast, in the ATTRACTION‑4 trial, the Asian population gained a prolongation of PFS but not of OS by adding IO to chemotherapy. In the CheckMate 649 study, patients (predominantly Caucasians) with advanced gastric, EGJC or EAC benefitted from the addition of nivolumab to chemotherapy in terms of overall survival (OS) and progression-free survival (PFS). For advanced disease, the KEYNOTE-590 trial revealed a benefit of adding pembrolizumab to chemotherapy for patients with locally advanced or metastatic adenocarcinoma (EAC) or squamous cell carcinoma of the esophagus (ESCC) or EGJC Siewert type 1. The CheckMate 577 trial, which was presented in EMSO Presidential Symposium III, showed a doubling in disease-free survival (DFS) for patients with resected esophageal (EC) or esophagogastric junction cancer (EGJC) following neoadjuvant chemoradiation therapy (CRT), who had not achieved a pathological complete response, treated with nivolumab versus placebo. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both the adjuvant and palliative setting. During this year’s virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |